Skip to main content

Nurix Therapeutics, Inc.

corporate_fare Company Profile

Nurix Therapeutics, Inc.

NRIX·NASDAQ·Life Sciences·CIK 0001549595

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering, developing, and selling targeted protein degradation medicines for cancer and inflammatory diseases. The company uses an artificial intelligence (AI)-integrated discovery engine and expertise in ligase to translate protein degradation science into clinical advancements. Nurix's wholly owned clinical pipeline includes three investigational drug candidates: bexobrutideg (NX-5948), a selective degrader of Bruton's tyrosine kinase (BTK); zelebrudomide (NX-2127), a dual degrader of BTK and transcription factors IKZF1 (Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase. The company is also developing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix's partnered drug discovery pipeline includes a clinical stage degrader of IRAK4 (NX-0479/GS-6791), a preclinical stage degrader of STAT6, and multiple undisclosed targets under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A., and Pfizer Inc. Nurix retains certain options for co-development, co-commercialization, and profit sharing in the United States for multiple drug candidates within these collaborations. Both wholly owned and partnered pipelines are powered by the DEL-AI discovery engine, which uses machine learning for DNA encoded library (DEL) hit-finding, degrader design, automated chemistry synthesis, and direct-to-biology screening and optimization to generate new chemical entity drug candidates.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 23 items for NRIX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 15 rated 8 or above. Recent SEC coverage for NRIX spans 8-K, 10-Q, 424B5.

Recent high-impact activity:

  • Sanofi Terminates SAR448272 STAT6 Degrader Program, Ending Nurix Milestone Stream
  • Sanofi Kills Phase 1 STAT6 Degrader, Wiping Out Nurix's SAR448272 Milestones
  • Nurix Q3: $549.8M Profit on Roche Upfront, $1.1B Cash, Bexobrutideg Enters Phase 3
  • Nurix Posts $549.8M Q3 Profit on Roche Upfront, Advances Bexobrutideg into Phase 3
  • Nurix Posts Surprise $4.73 Q3 Profit, Defying Loss Expectations

Financial Snapshot

Fiscal year ended November 30, 2025
Revenue
$83.98M
Net Income
-$264.46M
Diluted EPS
-$3.05
Op. Cash Flow
-$249.47M
Free Cash Flow
-$263.47M
Operating Income
-$285.67M
Cash & Equivalents
$246.96M
Debt / Equity
0.00×
Net Margin
-314.9%
Shares Outstanding
101.81M sh
Source: 10-K · filed 2026-01-28 · accession 0001549595-26-000016

Short Interest & Short Volume

7.17 days to cover

FINRA reported short interest of 18,936,583 shares in NRIX as of the October 30, 2026 settlement, a 8.1% decrease from the prior period — about 7.2 days to cover at its recent average daily volume. On November 19, 2026, 23.3% of NRIX volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)18,936,583 shares as of October 30, 2026
Change vs prior period▼ 8.1%
Days to cover7.17 at avg daily volume of 2,639,810
Daily short volume (FINRA facilities)23.3% of 701,612 shares on November 19, 2026
5-day average short volume37.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with N →
$12.93 -4.93% today
52-week range · as of 2026-11-03 $11.67 – $28.23
Market cap
$1.41B
Volume
1.1M (0.3× avg)
3-mo avg 3.6M
Live data · 2026-11-20 19:41 UTC · Market open

show_chartPrice Chart

Loading chart...

feed NRIX - Latest Insights

NRIX
Nov 03, 2026, 4:02 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $22.03
Real-time Price: $12.93 info
Change: -$9.10 (-41%) info
Market Cap: $1.413B info
NRIX
Nov 03, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $17.88
Real-time Price: $12.93 info
Change: -$4.95 (-28%) info
Market Cap: $1.413B info
NRIX
Oct 13, 2026, 6:21 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $12.93 info
Change: -$9.57 (-43%) info
Market Cap: $1.413B info
NRIX
Oct 13, 2026, 6:19 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $22.50
Real-time Price: $12.93 info
Change: -$9.57 (-43%) info
Market Cap: $1.413B info
NRIX
Oct 12, 2026, 4:05 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $23.06
Real-time Price: $12.93 info
Change: -$10.13 (-44%) info
Market Cap: $1.413B info
NRIX
Oct 05, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $22.96
Real-time Price: $12.93 info
Change: -$10.03 (-44%) info
Market Cap: $1.413B info
NRIX
Jul 21, 2026, 6:31 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $23.69
Real-time Price: $12.93 info
Change: -$10.76 (-45%) info
Market Cap: $1.413B info
NRIX
Jul 09, 2026, 4:12 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $24.82
Real-time Price: $12.93 info
Change: -$11.89 (-48%) info
Market Cap: $1.413B info
NRIX
Jul 09, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $24.82
Real-time Price: $12.93 info
Change: -$11.89 (-48%) info
Market Cap: $1.413B info
NRIX
Jul 09, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $24.82
Real-time Price: $12.93 info
Change: -$11.89 (-48%) info
Market Cap: $1.413B info
NRIX
Jun 11, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $16.75
Real-time Price: $12.93 info
Change: -$3.82 (-23%) info
Market Cap: $1.413B info
NRIX
Jun 11, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $15.64
Real-time Price: $12.93 info
Change: -$2.71 (-17%) info
Market Cap: $1.413B info
NRIX
Jun 08, 2026, 6:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $16.37
Real-time Price: $12.93 info
Change: -$3.44 (-21%) info
Market Cap: $1.413B info
NRIX
Jun 08, 2026, 6:11 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $16.40
Real-time Price: $12.93 info
Change: -$3.47 (-21%) info
Market Cap: $1.413B info
NRIX
Jun 08, 2026, 1:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $14.65
Real-time Price: $12.93 info
Change: -$1.72 (-12%) info
Market Cap: $1.413B info
NRIX
Apr 08, 2026, 6:03 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $12.93 info
Change: -$2.82 (-18%) info
Market Cap: $1.413B info
NRIX
Apr 08, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $12.93 info
Change: -$2.82 (-18%) info
Market Cap: $1.413B info
NRIX
Mar 06, 2026, 4:43 PM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $15.10
Real-time Price: $12.93 info
Change: -$2.17 (-14%) info
Market Cap: $1.413B info
NRIX
Mar 06, 2026, 4:40 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.10
Real-time Price: $12.93 info
Change: -$2.17 (-14%) info
Market Cap: $1.413B info
NRIX
Mar 06, 2026, 4:38 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $15.10
Real-time Price: $12.93 info
Change: -$2.17 (-14%) info
Market Cap: $1.413B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets